Caileigh Dougherty
Keine laufenden Positionen mehr
Profil
Caileigh Dougherty worked as Director-Investor Relations at Athenex, Inc. and as Head-Investor Relations at Intercept Pharmaceuticals, Inc.
Ehemalige bekannte Positionen von Caileigh Dougherty
| Unternehmen | Position | Ende |
|---|---|---|
| ATHENEXPAR | Public Communications Contact | 01.09.2022 |
| INTERCEPT PHARMACEUTICALS, INC. | Public Communications Contact | 01.08.2021 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Athenex, Inc.
 Athenex, Inc. Pharmaceuticals: MajorHealth Technology Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. | Health Technology |
